TIM-3 is expressed on immune cells and myeloid cells, so targeting it provides potential
to activate immune response and suppress leukemic cell proliferation.1,2
• Challenges facing current standard-of-care
therapies include poor overall survival,
Novartis is researching the role
limited duration of response, and singular
of TIM-3 in HR-MDS and AML.
mechanistic action3-6
• Additional approaches are needed to improve
See both sides at DualTIM3.com
treatment options and patient outcomes7-9
AML, acute myeloid leukemia; HR-MDS, high-risk myelodysplastic syndrome; TIM-3, T cell immunoglobulin and mucin domain-3.
References: 1. Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341-352. 2. Sakuishi K, Ngiow SF, Sullivan
JM, et al. TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849. 3. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic
syndromes. Semin Oncol. 2011;38(5):682-692. 4. Dinardo C, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. 5. Platzbecker U.
Treatment of MDS. Blood. 2019;133(10):1096-1107. 6. Fenaux P, Mufti G, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised,
open-label, phase Ill study. Lancet Oncol. 2009;10(3):223-232. 7. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53-61. 8. Faber MG, Griffiths EA, Thota S. Current state of myelodysplastic
syndromes: standard treatment practices and therapeutic advances. J Clin Pathways. 2019;5(6):43-47. 9. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol.
2019;10:2040620719827310.
Novartis��Pharma��AG Novartis��Pharmaceuticals��Corporation
���������������������������������������������������� �������������������������������� ���������� ���������������������������� ������������������������������������������������������������������������